吡柔比星热灌注联合全身化疗治疗晚期膀胱癌的疗效与安全性评价

发布时间：2018-01-17 23:32

本文关键词：吡柔比星热灌注联合全身化疗治疗晚期膀胱癌的疗效与安全性评价　出处：《中国临床药理学杂志》2015年03期 　论文类型：期刊论文

【摘要】：目的评价吡柔比星热灌注联合全身化疗对晚期膀胱癌患者的临床疗效及不良反应。方法收治晚期膀胱癌患者47例,单纯吉西他滨+顺铂(GP)方案全身化疗者24例(对照组),GP联合吡柔比星热灌注化疗者23例(试验组)。对照组:第1,8天静脉滴注吉西他滨1000 mg·m-2;第2,3,4天静脉滴注顺铂30 mg·m-2,28 d为1个周期,化疗4个周期;治疗组:在对照组的基础上膀胱内灌注吡柔比星20 mg,每周1次,共8周。评价2组患者的客观疗效及不良反应。结果化疗4个周期后,治疗组客观有效率为78.3%,对照组为41.7%,治疗组显著高于对照组(P0.05)。治疗组和对照组组患者各项药品不良反应发生率分别为17.4%和20.8%,差异无统计学意义(P0.05)。结论吡柔比星热灌注联合GP方案治疗可显著提高晚期膀胱癌患者的临床疗效且不增加相关不良反应。
[Abstract]:Objective to evaluate the clinical efficacy and adverse reactions of pirarubicin combined with systemic chemotherapy in the treatment of advanced bladder cancer. Methods 47 patients with advanced bladder cancer were treated. There were 24 cases of systemic chemotherapy with gemcitabine cisplatin alone (23 cases of control group treated with GP combined with pirarubicin) (experimental group: control group: 1). 8 days drip gemcitabine 1000mg 路m-2; Cisplatin (30 mg 路m ~ (-2)) was injected intravenously on the 3rd day of the second trimester for 28 days as one cycle and chemotherapy for 4 cycles. Treatment group: intravesical intravesical instillation of pirarubicin 20 mg once a week for 8 weeks on the basis of control group. Objective efficacy and adverse reactions were evaluated in both groups. Results after 4 cycles of chemotherapy. The objective effective rate was 78.3 in the treatment group and 41.7% in the control group. The incidence of adverse drug reactions in treatment group and control group were 17.4% and 20.8% respectively. Conclusion Thermoperfusion of pirarubicin combined with GP regimen can significantly improve the clinical efficacy of patients with advanced bladder cancer without increasing the related adverse reactions.
【作者单位】：泸州医学院附属中医医院外五科;
【基金】：泸州医学院附属中医医院联合科研基金资助项目(2013-S-47)
【分类号】：R737.14
【正文快照】： 膀胱癌是泌尿外科常见疾病,晚期转移性膀胱癌患者大多全身化疗或局部灌注化疗[1]。常用化疗药物有吉西他滨、顺铂、吡柔比星等,上述药物化疗疗效及不良反应发生率不近相同。吡柔比星为细胞毒类药物,作用于细胞DNA,主要是进入细胞内,迅速分布于细胞核,抑制DNA聚合酶α,阻碍核酸

【共引文献】